BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79:1686-1695. [PMID: 17854035 DOI: 10.1002/jmv.20979] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Takayama T, Ebinuma H, Tada S, Yamagishi Y, Wakabayashi K, Ojiro K, Kanai T, Saito H, Hibi T; Keio Association for the Study of Liver Diseases. Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection. PLoS One 2011;6:e27223. [PMID: 22164207 DOI: 10.1371/journal.pone.0027223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
2 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
3 Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H, Chayama K. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon a-2b to a-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report. Intervirology 2012;55:122-6. [DOI: 10.1159/000328661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T, Maehara Y. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant. J Viral Hepat 2014;21:397-404. [PMID: 24750545 DOI: 10.1111/jvh.12154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
5 Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52:864-874. [PMID: 20568303 DOI: 10.1002/hep.23787] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 7.5] [Reference Citation Analysis]
6 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol. 2008;80:1354-1362. [PMID: 18551609 DOI: 10.1002/jmv.21202] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
7 Asada A, Shioya M, Osaki R, Nishimura T, Takeuchi T, Okumura Y, Andoh A. MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection. Biomed Rep 2015;3:247-53. [PMID: 26075078 DOI: 10.3892/br.2014.406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J Gastroenterol Hepatol. 2013;28:51-56. [PMID: 22989264 DOI: 10.1111/j.1440-1746.2012.07267.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
9 Kogure T, Ueno Y, Fukushima K, Nagasaki F, Kondo Y, Inoue J, Matsuda Y, Kakazu E, Yamamoto T, Onodera H, Miyazaki Y, Okamoto H, Akahane T, Kobayashi T, Mano Y, Iwasaki T, Ishii M, Shimosegawa T. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 2008; 14(47): 7225-7230 [PMID: 19084938 DOI: 10.3748/wjg.14.7225] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
10 Toyoda H, Kumada T, Tada T, Kawaguchi T, Murakami Y, Matsuda F. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. J Med Virol 2011;83:1203-11. [PMID: 21567424 DOI: 10.1002/jmv.22092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009;104:598-604. [PMID: 19262519 DOI: 10.1038/ajg.2008.125] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
12 Abdo AA, Sanai FM. Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects. Ann Saudi Med 2009;29:1-3. [PMID: 19139625 DOI: 10.4103/0256-4947.51810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
13 Shaala AY, Morsi MG, Harfoush RAH, Elkhouly EH, Ahmed MAR, Roshdy MN. Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis. Alexandria Journal of Medicine 2015;51:231-9. [DOI: 10.1016/j.ajme.2014.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Simoes P, Asaad A, Abed J, Engelson ES, Kotler DP. Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population. Womens Health Issues 2015;25:289-93. [PMID: 25965157 DOI: 10.1016/j.whi.2015.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Nakagawa A, Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Arai T, Hashimoto S, Matsushita Y, Fukuda T, Nakatsuka K, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. Eur J Gastroenterol Hepatol 2014;26:1329-34. [PMID: 25357216 DOI: 10.1097/MEG.0000000000000228] [Reference Citation Analysis]
16 Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Takahashi S, Arihiro K, Chayama K. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases: CAP measurement for liver steatosis. Hepatol Res 2013;43:1182-9. [DOI: 10.1111/hepr.12094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
17 Pascarella S, Clément S, Guilloux K, Conzelmann S, Penin F, Negro F. Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: Comparison between different genotypes and core protein sequence analysis. J Med Virol 2011;83:1005-15. [DOI: 10.1002/jmv.22072] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
18 Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, Mita E, Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. J Med Virol 2011;83:419-27. [DOI: 10.1002/jmv.21975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
19 Tada S, Saito H, Ebinuma H, Ojiro K, Yamagishi Y, Kumagai N, Inagaki Y, Masuda T, Nishida J, Takahashi M. Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism. Hepatol Res. 2009;39:195-199. [PMID: 19054155 DOI: 10.1111/j.1872-034x.2008.00439.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
20 Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat. 2013;20:761-769. [PMID: 24168255 DOI: 10.1111/jvh.12097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
21 Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol. 2011;26 Suppl 1:83-95. [PMID: 21199518 DOI: 10.1111/j.1440-1746.2010.06550.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
22 Ogawa E, Furusyo N, Hayashi J, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S. An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Journal of Infection and Chemotherapy 2012;18:689-97. [DOI: 10.1007/s10156-012-0396-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
23 Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, Koike K. Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation. Sci Rep. 2012;2:637. [PMID: 22957141 DOI: 10.1038/srep00637] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
24 Fukuhara T, Taketomi A, Okano S, Ikegami T, Soejima Y, Shirabe K, Maehara Y. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol. 2010;52:672-680. [PMID: 20346532 DOI: 10.1016/j.jhep.2009.10.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
25 Kawaoka T, Hiraga N, Takahashi S, Takaki S, Mitsui F, Tsuge M, Nagaoki Y, Kimura Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Tashiro H, Ohdan H, Chayama K. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scandinavian Journal of Gastroenterology 2010;45:1488-96. [DOI: 10.3109/00365521.2010.505657] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
26 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009;81:1032-9. [PMID: 19382270 DOI: 10.1002/jmv.21473] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
27 Khaliq S, Jahan S, Pervaiz A. Sequence variability of HCV Core region: Important predictors of HCV induced pathogenesis and viral production. Infection, Genetics and Evolution 2011;11:543-56. [DOI: 10.1016/j.meegid.2011.01.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
28 Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Aizawa Y. Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. J Postgrad Med 2016;62:20-5. [PMID: 26732192 DOI: 10.4103/0022-3859.173191] [Reference Citation Analysis]
29 Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. J Med Virol. 2014;86:461-472. [PMID: 24166425 DOI: 10.1002/jmv.23824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
30 Abdel-Razik A, Mousa N, Abdel-Aziz M, Elhelaly R, Elzehery R, Zalata K, Elkashef W, Fouda O, Awad M, Hafez M, Eldars W. Elevated serum α-fetoprotein levels in patients with chronic hepatitis C virus genotype 4: not the end of the story. Eur J Gastroenterol Hepatol 2016;28:313-22. [PMID: 26618566 DOI: 10.1097/MEG.0000000000000534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, Tsuge M, Mitsui F, Hiraga N, Imamura M. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol. 2011;54:408-414. [PMID: 21112660 DOI: 10.1016/j.jhep.2010.07.032] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
32 Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485 [PMID: 29632428 DOI: 10.3748/wjg.v24.i13.1478] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139:1577-1585, 1585.e1-3. [PMID: 20708617 DOI: 10.1053/j.gastro.2010.07.058] [Cited by in Crossref: 173] [Cited by in F6Publishing: 160] [Article Influence: 14.4] [Reference Citation Analysis]
34 Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinohara Y, Sasaki H, Iida H, Takahashi H, Inamori M, Abe Y, Kobayashi N, Kubota K, Kirikoshi H, Nakajima A, Saito S. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. Journal of Viral Hepatitis 2010;17:274-9. [DOI: 10.1111/j.1365-2893.2009.01179.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
35 Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Dig Liver Dis. 2014;46:738-743. [PMID: 24880716 DOI: 10.1016/j.dld.2014.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
36 Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, Ben Mami N, Triki H, Chouchane L. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy. J Med Virol 2009;81:2021-8. [PMID: 19856481 DOI: 10.1002/jmv.21641] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
37 Eng FJ, Walewski JL, Klepper AL, Fishman SL, Desai SM, McMullan LK, Evans MJ, Rice CM, Branch AD. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol. 2009;83:3104-3114. [PMID: 19129450 DOI: 10.1128/jvi.01679-08] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
38 Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010;82:41-8. [DOI: 10.1002/jmv.21629] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
39 Kobayashi M, Suzuki F, Akuta N, Suzuki Y, Sezaki H, Yatsuji H, Kawamura Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Mineta R, Iwasaki S, Watahiki S, Miyakawa Y, Kumada H. Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. Scandinavian Journal of Gastroenterology 2009;44:975-83. [DOI: 10.1080/00365520802588125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
40 Hiasa Y, Kuzuhara H, Tokumoto Y, Konishi I, Yamashita N, Matsuura B, Michitaka K, Chung RT, Onji M. Hepatitis C virus replication is inhibited by 22β-methoxyolean-12-ene-3β, 24(4β)-diol (ME3738) through enhancing interferon-β. Hepatology 2008;48:59-69. [DOI: 10.1002/hep.22289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
41 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J Med Virol 2008;80:1363-9. [PMID: 18551610 DOI: 10.1002/jmv.21224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
42 Njouom R, Sartre MT, Timba I, Nerrienet E, Tchendjou P, Pasquier C, Rousset D. Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C. J Med Virol 2008;80:2079-85. [DOI: 10.1002/jmv.21319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
43 Saleh MI, Bani Melhim S. A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. J Chemother 2019;31:274-83. [PMID: 31070545 DOI: 10.1080/1120009X.2019.1609739] [Reference Citation Analysis]
44 Fialho R, Pereira M, Gilleece Y, Rusted J, Whale R. A longitudinal study assessing depression in hepatitis C: Does gender play a role in the new-onset depression during interferon-alpha treatment? Women Health 2019;59:181-95. [PMID: 29630491 DOI: 10.1080/03630242.2018.1449778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-368. [PMID: 20394674 DOI: 10.1111/j.1872-034x.2010.00642.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
46 Ozeki I, Nakajima T, Yamaguchi M, Kimura M, Arakawa T, Kuwata Y, Ohmura T, Sato T, Hige S, Karino Y, Toyota J. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy. Hepatol Res 2016;46:1162-7. [PMID: 26857426 DOI: 10.1111/hepr.12667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol 2011;83:445-52. [PMID: 21264865 DOI: 10.1002/jmv.22005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
48 Saigal S, Choudhary NS, Saraf N, Gautam D, Lipi L, Rastogi A, Goja S, Menon PB, Bhangui P, Ramachandra SK, Soin AS. Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation. Indian J Gastroenterol 2015;34:305-9. [DOI: 10.1007/s12664-015-0578-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
49 Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol. 2012;27:1467-1472. [PMID: 22432893 DOI: 10.1111/j.1440-1746.2012.07129.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
51 Miyake Y, Ando M, Kaji E, Toyokawa T, Nakatsu M, Hirohata M. Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res. 2008;38:980-986. [PMID: 18657124 DOI: 10.1111/j.1872-034x.2008.00357.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
52 Khairy M, Fouad R, Mabrouk M, El-Akel W, Awad AB, Salama R, Elnegouly M, Shaker O. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis. Hepat Mon 2013;13:e10509. [PMID: 24065997 DOI: 10.5812/hepatmon.10509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
53 Khaliq S, Latief N, Jahan S. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. Arch Virol. 2014;159:1-15. [PMID: 23851652 DOI: 10.1007/s00705-013-1780-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
54 Akamatsu S, Hayes CN, Ochi H, Uchida T, Kan H, Murakami E, Abe H, Tsuge M, Miki D, Akiyama R, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama K. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. Journal of Hepatology 2015;63:554-63. [DOI: 10.1016/j.jhep.2015.03.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
55 Alestig E, Arnholm B, Eilard A, Lagging M, Nilsson S, Norkrans G, Wahlberg T, Wejstål R, Westin J, Lindh M. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011;11:124. [PMID: 21569441 DOI: 10.1186/1471-2334-11-124] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
56 Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon 2013;13:e14872. [PMID: 24403915 DOI: 10.5812/hepatmon.14872] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
57 Alezzi ZMM, Abd El Rehim AY, Fathallah WF, Alamrani MA, Othman FH. Factors Affecting the Virological Response Among Chronic Hepatitis C Virus Patients in Yemen. J Interferon Cytokine Res 2018;38:38-44. [PMID: 29328881 DOI: 10.1089/jir.2017.0098] [Reference Citation Analysis]
58 Utama A, Tania NP, Dhenni R, Gani RA, Hasan I, Sanityoso A, Lelosutan SA, Martamala R, Lesmana LA, Sulaiman A, Tai S. Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia. Liver Int 2010;30:1152-60. [PMID: 20492518 DOI: 10.1111/j.1478-3231.2010.02280.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
59 Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009;44:1009-1015. [PMID: 19756352 DOI: 10.1007/s00535-009-0126-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
60 Angelico F, Francioso S, Del Ben M, Feole K, Carbone M, Pignatelli P, Violi F, Angelico M. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther. 2009;30:444-451. [PMID: 19493257 DOI: 10.1111/j.1365-2036.2009.04055.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
61 Chen T, Huang P, Wen C, Tung J, Chow K, Chen Y. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy: PKRBD in CHC with individualized therapy. Journal of Viral Hepatitis 2011;18:119-28. [DOI: 10.1111/j.1365-2893.2010.01287.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Serre SB, Krarup HB, Bukh J, Gottwein JM. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J Virol 2013;87:12776-93. [PMID: 24049176 DOI: 10.1128/JVI.00901-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
63 Chu PS, Ebinuma H, Nakamoto N, Sugiyama K, Usui S, Wakayama Y, Taniki N, Yamaguchi A, Shiba S, Yamagishi Y, Wakita T, Hibi T, Saito H, Kanai T. Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. PLoS One 2015;10:e0125664. [PMID: 25965701 DOI: 10.1371/journal.pone.0125664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Hu Z, Liu Y, Qiu L, Fan Z, Nie W, Liang S, Jin R. Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b. Virol J 2014;11:148. [PMID: 25128407 DOI: 10.1186/1743-422X-11-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology. 2012;55:417-425. [PMID: 21325786 DOI: 10.1159/000323526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
66 Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 2011;46:401-9. [PMID: 20830599 DOI: 10.1007/s00535-010-0322-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
67 Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009;54:1317-1324. [PMID: 18958621 DOI: 10.1007/s10620-008-0500-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
68 Mori K, Ueda Y, Ariumi Y, Dansako H, Ikeda M, Kato N. Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C. Virus Genes 2012;44:374-81. [DOI: 10.1007/s11262-012-0712-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
69 Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol 2012;47:1014-21. [PMID: 22382633 DOI: 10.1007/s00535-012-0560-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
70 Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouso K, Iwasaki Y. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro. Liver Int. 2010;30:1324-1331. [PMID: 20602680 DOI: 10.1111/j.1478-3231.2010.02299.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
71 Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009;54:1317-1324. [PMID: 18958621 DOI: 10.1007/s10620-008-0500y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Shaker O, El-Shehaby A, Fayez S, Zahra A, Marzouk S, El Raziky M. Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4. Cell Biochem Funct. 2013;31:620-625. [PMID: 23400862 DOI: 10.1002/cbf.2954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
73 Nomura H, Miyagi Y, Tanimoto H, Higashi M, Ishibashi H. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol 2009;44:338-45. [DOI: 10.1007/s00535-009-0008-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
74 Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol. 2012;47:834-844. [PMID: 22350701 DOI: 10.1007/s00535-012-0550-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
75 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012;55:231-241. [PMID: 21734353 DOI: 10.1159/000328327] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]